6620.TWO Handa Pharmaceuticals Inc.
- Market cap
- TWD 16.1B
- P/E
- 35.8x
- P/B
- 4.00x
- ROE
- 4.3%
- Dividend yield
- 1.47%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6620.TWO undervalued?
Graham number6620.TWO trades 152.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Handa Pharmaceuticals Inc. fundamental analysis
No fundamental analysis for Handa Pharmaceuticals Inc. yet.
Handa Pharmaceuticals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Handa Pharmaceuticals Inc.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple scl…
Full company profileHanda Pharmaceuticals Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Handa Pharmaceuticals Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 29.2M | 198M | 1.11B | 831M | 1.73B | 843M |
| Gross Profit | 27.8M | 179M | 1.11B | 830M | 1.46B | 679M |
| Operating Income | -254M | -88.1M | 693M | 418M | 934M | 214M |
| EBITDA | - | -27.7M | 805M | 490M | 1.10B | 488M |
| Net Income | -248M | -40.0M | 727M | 473M | 750M | 216M |
| EPS | -1.98 | -0.30 | 5.15 | 3.37 | 4.45 | 1.33 |
| Balance Sheet | ||||||
| Total Assets | 499M | 791M | 3.04B | 3.44B | 5.89B | 5.58B |
| Total Liabilities | 35.4M | 69.4M | 281M | 324M | 232M | 558M |
| Shareholders' Equity | 463M | 721M | 2.76B | 3.12B | 5.66B | 5.02B |
| Cash & Short-term Investments | 263M | 366M | 667M | 597M | 1.81B | 1.50B |
| Cash Flow | ||||||
| Operating Cash Flow | -179M | -212M | 668M | 498M | 244M | 980M |
| Capital Expenditure | 7.15M | 758K | 944K | 7.77M | 17.1M | 42.2M |
| Free Cash Flow | -186M | -212M | 667M | 490M | 227M | 938M |
| Ratios | ||||||
| ROE | -53.5% | -5.5% | 26.4% | 15.2% | 13.2% | 4.3% |
| ROA | -49.7% | -5.1% | 23.9% | 13.7% | 12.7% | 3.9% |
| Net Profit Margin | -847.2% | -20.2% | 65.7% | 56.9% | 43.4% | 25.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Handa Pharmaceuticals Inc. dividends
- Dividend yield
- 1.47%
- Forward dividend
- 2.07 TWD
- Payout ratio
- 31.5%
- Ex-dividend date
- Jul 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 236M | 1.40 | 31.5% |
| 2024 | TWD 141M | 1.00 | 29.8% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Handa Pharmaceuticals Inc.
- Insiders 42.05%
- Institutions 1.23%
- Public & others 56.72%
- Shares outstanding 163M
- Free float 92.9M
Handa Pharmaceuticals Inc. company profile
- Company name
- Handa Pharmaceuticals Inc.
- Ticker
- 6620.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- No.23, Nanke 3rd Road, Tainan City, Taiwan, 744094
- Phone
- 886 6 505 7508
- Website
- handapharma.com.tw
About Handa Pharmaceuticals Inc.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; Varenicline tablet and HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
Handa Pharmaceuticals Inc. management
5- Mr. Fang-Yu Liu Ph.D.Founder & Chairman
- Mr. Toshiyo ChenGM & Director
- Ms. Chi-Yu YangVP of Finance & Accounting Officer
- Dr. Guo-Chun Song Ph.D.Chief Technology Officer
- Ms. Mei-Fang Chang Ph.D.Senior VP of Quality Affairs & Director